FDA demands more data on Novartis's ACZ885

Novartis's ($NVS) plans to expand the use of ACZ885 in a drive to achieve blockbuster status ran into a roadblock this morning. The pharma giant says that the FDA handed the company a complete response letter detailing its demands for more data on gouty arthritis patients ahead of any final decision on the treatment. The FDA wants more data on the clinical risk/benefit in refractory patients. An expert panel voted in favor of the drug's efficacy back in June but noted the need for more safety data. Report

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.